ICH Q12
ICH Q12 Lifecycle Management (Established Conditions)
What a definition is not
A definition is SPEQ’s plain-language decode of how a term is used in practice, cited to the documents that define it. It is a practitioner reference, not legal or regulatory advice, it does not replace the definition in the source, and where a regulator’s wording differs the regulator’s wording governs.
ICH Q12 provides a framework and tools for managing post-approval chemistry, manufacturing, and controls (CMC) changes in a more predictable and efficient way across the product lifecycle. Its central concepts are established conditions (the legally binding information a regulator needs to be notified of if changed) and the post-approval change management protocol (PACMP), together with a product lifecycle management document. The goal is to let low-risk changes be managed under a firm's pharmaceutical quality system rather than each requiring a prior-approval regulatory submission.
Q12 tries to solve a real friction: many beneficial, low-risk manufacturing improvements historically required regulatory submissions disproportionate to their risk. By defining what is and is not an established condition, it clarifies the reporting category a given change attracts.
Adoption and legal effect vary by region because it interacts with each authority's existing variation/change framework — implementation is not uniform across ICH members.
- —Established conditions = the information a change to which requires notification
- —PACMP pre-agrees the plan for a future change
- —Aims to shift low-risk changes into the PQS, not the submission queue
- —Regional legal implementation differs
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; regional legal implementation varies (FDA/EMA).
Frequently asked questions
What does ICH Q12 stand for?
ICH Q12 stands for ICH Q12 Lifecycle Management (Established Conditions).
What is ICH Q12?
ICH Q12 provides a framework and tools for managing post-approval chemistry, manufacturing, and controls (CMC) changes in a more predictable and efficient way across the product lifecycle. Its central concepts are established conditions (the legally binding information a regulator needs to be notified of if changed) and the post-approval change management protocol (PACMP), together with a product lifecycle management document. The goal is to let low-risk changes be managed under a firm's pharmaceutical quality system rather than each requiring a prior-approval regulatory submission.
Which regulations cover ICH Q12?
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; regional legal implementation varies (FDA/EMA).